Zhengye Biotech Reports High Q1’26 Profit Margin Gains
Improving Margins Amid Revenue Challenges Alright, let’s cut to the chase. Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) had a bit of a mixed bag in their latest financial outing. Their net revenues fell off a cliff by 18.3%, landing at RMB50.9 million (about $7.5 million), down from a healthier RMB62.3 million from the previous year. But don’t hang up your...
Continue Reading